<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615378</url>
  </required_header>
  <id_info>
    <org_study_id>Pro50335</org_study_id>
    <nct_id>NCT03615378</nct_id>
  </id_info>
  <brief_title>Maintenance Dosing of Vitamin D in Crohn's Disease</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial Evaluating Optimal Maintenance Strategies of Vitamin D Levels in Patients With Crohn's Disease in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D repletion is important for bone health in patients with Crohn's disease. While
      repletion strategies in the general population yield similar results in those with Crohn's
      disease, maintenance strategies are variable. High quality evidence is lacking to determine
      the optimal strategy to maintain adequate levels of Vitamin D levels in patients with Crohn's
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators seek to identify patients with Crohn's disease in clinical remission who
      have vitamin D levels &lt;30 ng/ml. Subjects will undergo a 8 week lead in period and receive
      Vitamin D supplementation with 50,000 IU D2 weekly for 8 weeks.Participants with sufficient
      Vitamin D levels after 8 weeks (&gt;30 ng/mL) will be enrolled into the study and randomized to
      one of three arms: (1) placebo (2) 1000 IU/day Vitamin D3 (3) 5,000 IU/day Vitamin D3 for 22
      weeks. Based on clinical experience, doses higher than the recommended doses for bone health
      in the general population (600-800 IU/day Vitamin D3) are needed to achieve and maintain
      optimal levels of Vitamin D in people with Crohn's disease.

      The investigators aim to determine optimal maintenance dosing to sustain vitamin D
      sufficiency in people with Crohn's disease. The investigators also seek to determine
      demographic and disease related characteristics associated with inability to maintain
      sufficient levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties with enrollment
  </why_stopped>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D serum level Vitamin D sufficiency</measure>
    <time_frame>22 weeks</time_frame>
    <description>Serum level greater than or equal to 30 ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Vitamin D Insufficiency</measure>
    <time_frame>22 weeks</time_frame>
    <description>Time (in weeks) from the measurement of sufficiency (at week 0) to Vitamin D insufficiency (defined as serum vitamin D level less than 30 ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Crohns Disease</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 1000 IU D3 daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 5000 IU D3 daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>5000 IU D3</intervention_name>
    <description>Daily</description>
    <arm_group_label>Vitamin D 5000 IU D3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1000 IU D3</intervention_name>
    <description>Daily</description>
    <arm_group_label>Vitamin D 1000 IU D3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose/sugar tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Crohn's disease

          2. In clinical remission as determined by the Harvey Bradshaw Index (CD) ≤4

          3. 25(OH)D level &lt;30 ng/ml within three months of study enrollment

          4. Prior 25(OH)D level &lt;30 ng/ml currently on repletion therapy

          5. Provided written informed consent

          6. 18 years of age or older

          7. All maintenance therapies required to be on stable doses for 3 months.

        Exclusion Criteria:

          1. Unwilling to provide consent or lack capacity

          2. Clinical disease activity (Harvey Bradshaw index &gt;4)

          3. Current pregnancy or attempting to conceive

          4. Hypercalcemia (must have calcium level within 6 months of enrollment)

          5. Known coexisting hyperparathyroidism

          6. BMI &gt;30 kg/m²

          7. History of kidney stones

          8. Subjects &lt;18 years of age - pediatric population with different recommended dosing
             than adults

          9. Non-english speakers

         10. Has an ileo-anal pouch or ileostomy

         11. C-reactive protein greater than 2x the upper limit of normal

         12. Lactose intolerant

         13. Short gut syndrome

         14. Renal insufficiency (CrCl &lt;60 ml/min)

         15. Concomitant therapy with thiazide diuretics, barbiturates, digitalis or supplemental
             products containing vitamin D

         16. Vitamin D levels &lt;30ng/ml at completion of lead in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GIl Y Melmed, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Gil Melmed</investigator_full_name>
    <investigator_title>Clinical Director of Inflammatory Bowel Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No information will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

